See What HealthDay Can Do For You
Contact Us

June 2008 Briefing - Rheumatology

Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for June 2008. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Proteins Mediate Inflammatory Response in Arthritis Model

FRIDAY, June 27 (HealthDay News) -- Two proteins involved in the recognition of pathogens are also involved in the inflammatory response in a mouse model of arthritis, according to study findings published online June 23 in the Proceedings of the National Academy of Sciences Early Edition.

Abstract
Full Text (subscription or payment may be required)

Rivaroxaban Found Superior to Enoxaparin

WEDNESDAY, June 25 (HealthDay News) -- In patients undergoing either total hip replacement or total knee replacement, thromboprophylaxis with rivaroxaban is significantly more effective at preventing adverse events than thromboprophylaxis with enoxaparin, according to two studies published in the June 26 issue of the New England Journal of Medicine and one study published online June 25 in The Lancet.

Abstract - Eriksson
Full Text (subscription or payment may be required)
Abstract - Lassen
Full Text (subscription or payment may be required)
Abstract - Kakkar
Full Text (subscription or payment may be required)
Editorial

Prediction Rule Identifies Risk of Osteoporotic Fracture

WEDNESDAY, June 25 (HealthDay News) -- A prediction rule based on a heel stiffness index and four clinical factors can identify which elderly women are at high risk of osteoporotic fracture, according to a report in the July issue of Radiology.

Abstract
Full Text (subscription or payment may be required)

Article Examines Use of 'Key Opinion Leaders' in Drug Sales

FRIDAY, June 20 (HealthDay News) -- Influential doctors known as "key opinion leaders" are paid generous fees to influence their peers to prescribe a company's drugs and may in fact be considered salespeople by the industry, according to an article in the June 21 issue of BMJ.

Full Text - Moynihan
Editorial - Buckwell
Editorial - Fava

Myeloma Drug Relieves Lupus Pathology in Mice

WEDNESDAY, June 11 (HealthDay News) -- Treating mice with lupus with bortezomib, a drug approved to treat multiple myeloma, eliminates autoreactive plasma cells, reduces glomerulonephritis and improves survival, according to study findings published online June 8 in Nature Medicine.

Abstract
Full Text (subscription or payment may be required)

Knee Problems Linked to Cartilage Loss in Osteoarthritis

FRIDAY, June 6 (HealthDay News) -- Medial meniscal damage and varus malalignment, and lateral meniscal damage predicted tibial and femoral cartilage loss over a two-year period in patients with knee osteoarthritis, according to research published in the June issue of Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)

Alcohol May Protect Against Rheumatoid Arthritis

FRIDAY, June 6 (HealthDay News) -- Alcohol consumption reduces the risk of rheumatoid arthritis, particularly in smokers, with the degree of reduction dependent on the amount of alcohol consumed, according to a report published online June 5 in the Annals of the Rheumatic Diseases.

Abstract
Full Text (subscription or payment may be required)

B Cell Subsets Point to Effects of Rituximab

THURSDAY, June 5 (HealthDay News) -- In people with rheumatoid arthritis, the behavior of certain memory B cell subsets may play a role in the efficacy of rituximab, response to the drug and disease relapse after taking it, according to research published in the June issue of Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)

Methotrexate for Rheumatoid Arthritis Linked to Cancer Risk

THURSDAY, June 5 (HealthDay News) -- Rheumatoid arthritis patients treated with methotrexate have a higher risk of developing cancer than the general population, particularly melanoma, non-Hodgkin's lymphoma and lung cancer, researchers report in the June 15 issue of Arthritis Care & Research.

Abstract
Full Text (subscription or payment may be required)

FDA Performing Safety Review of TNF Blockers

WEDNESDAY, June 4 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) is performing a safety review of drugs that block tumor necrosis factor (TNF), used to treat diseases such as arthritis and psoriasis, due to reports of cancers in young patients prescribed the drugs.

More Information

Low-Dose Rotigotine Can Help Treat Restless Legs Syndrome

MONDAY, June 2 (HealthDay News) -- Both the daytime and nighttime symptoms of restless legs syndrome can be relieved using a 24-hour transdermal patch containing low-dose rotigotine, according to study findings published online May 31 in The Lancet Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing
undefined
undefinedundefined